	US 12,391,741 B2
	T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
Marc van Dijk, Bosch en Duin (NL); Ekaterina Vladimirovna Breous-Nystrom, Basel (CH); Alessandra Franchino, Basel (CH); Sébastien Lalevée, Saint Louis (FR); Arthur Andrew Hurwitz, Bedford, MA (US); Mark Adrian Exley, Brookline, MA (US); and Benjamin Jacob Wolf, Boston, MA (US)
Assigned to MiNK Therapeutics, Inc., New York, NY (US)
Filed by MiNK Therapeutics, Inc., New York, NY (US)
Filed on Jun. 23, 2023, as Appl. No. 18/340,600.
Application 18/340,600 is a division of application No. 16/807,742, filed on Mar. 3, 2020, granted, now 11,718,658.
Application 16/807,742 is a continuation of application No. PCT/US2018/049397, filed on Sep. 4, 2018.
Claims priority of provisional application 62/553,957, filed on Sep. 4, 2017.
Prior Publication US 2024/0301025 A1, Sep. 12, 2024
Int. Cl. C07K 14/725 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); C12N 15/63 (2006.01)

CPC C07K 14/7051 (2013.01) [C12N 15/63 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); C07K 2317/565 (2013.01)]

20 Claims

1. A method of treating cancer in a subject, the method comprising administering to the subject an engineered cell comprising a T cell receptor (TCR) that comprises:

(a) a CDR1α comprising the amino acid sequence of SEQ ID NO: 11, a CDR2α comprising the amino acid sequence of SEQ ID NO: 16, a CDR3α comprising the amino acid sequence of SEQ ID NO: 21, a CDR1β comprising the amino acid sequence of SEQ ID NO: 26, a CDR2β comprising the amino acid sequence of SEQ ID NO: 31, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 36;

(b) a CDR1α comprising the amino acid sequence of SEQ ID NO: 12, a CDR2α comprising the amino acid sequence of SEQ ID NO: 17, a CDR3α comprising the amino acid sequence of SEQ ID NO: 22, a CDR1β comprising the amino acid sequence of SEQ ID NO: 27, a CDR2β comprising the amino acid sequence of SEQ ID NO: 32, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 37;

(c) a CDR1α comprising the amino acid sequence of SEQ ID NO: 13, a CDR2α comprising the amino acid sequence of SEQ ID NO: 18, a CDR3α comprising the amino acid sequence of SEQ ID NO: 23, a CDR1β comprising the amino acid sequence of SEQ ID NO: 28, a CDR2β comprising the amino acid sequence of SEQ ID NO: 33, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 38;

(d) a CDR1α comprising the amino acid sequence of SEQ ID NO: 13, a CDR2α comprising the amino acid sequence of SEQ ID NO: 109, a CDR3α comprising the amino acid sequence of SEQ ID NO: 23, a CDR1β comprising the amino acid sequence of SEQ ID NO: 28, a CDR2β comprising the amino acid sequence of SEQ ID NO: 33, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 38;

(e) a CDR1α comprising the amino acid sequence of SEQ ID NO: 14, a CDR2α comprising the amino acid sequence of SEQ ID NO: 19, a CDR3α comprising the amino acid sequence of SEQ ID NO: 24, a CDR1β comprising the amino acid sequence of SEQ ID NO: 29, a CDR2β comprising the amino acid sequence of SEQ ID NO: 34, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 39; or

(f) a CDR1α comprising the amino acid sequence of SEQ ID NO: 15, a CDR2α comprising the amino acid sequence of SEQ ID NO: 20, a CDR3α comprising the amino acid sequence of SEQ ID NO: 25, a CDR1β comprising the amino acid sequence of SEQ ID NO: 30, a CDR2β comprising the amino acid sequence of SEQ ID NO: 35, and a CDR3β comprising the amino acid sequence of SEQ ID NO: 40.